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Abstract
Objectives. To assess underlying domains measured by GaitSmartTMparameters and whether these are additional
to established OA markers including patient reported outcome measures (PROMs) and radiographic parameters,
and to evaluate if GaitSmart analysis is related to the presence and severity of radiographic knee OA.
Methods. GaitSmart analysis was performed during baseline visits of participants of the APPROACH cohort
(n¼297). Principal component analyses (PCA) were performed to explore structure in relationships between
GaitSmart parameters alone and in addition to radiographic parameters and PROMs. Logistic and linear regression
analyses were performed to analyse the relationship of GaitSmart with the presence (Kellgren and Lawrence grade
2 in at least one knee) and severity of radiographic OA (ROA).
Results. Two hundred and eighty-four successful GaitSmart analyses were performed. The PCA identified five
underlying GaitSmart domains. Radiographic parameters and PROMs formed additional domains indicating that
GaitSmart largely measures separate concepts. Several GaitSmart domains were related to the presence of ROA
as well as the severity of joint damage in addition to demographics and PROMs with an area under the receiver
operating characteristic curve of 0.724 and explained variances (adjusted R2) of 0.107, 0.132 and 0.147 for min-
imum joint space width, osteophyte area and mean subchondral bone density, respectively.
Conclusions. GaitSmart analysis provides additional information over established OA outcomes. GaitSmart
parameters are also associated with the presence of ROA and extent of radiographic severity over demographics
and PROMS. These results indicate that GaitsmartTM may be an additional outcome measure for the evaluation of
OA.
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Rheumatology key messages
. GaitSmartTM provides additional information above parameters currently used to assess OA.
. GaitSmart is associated with the presence and to a limited extent severity of radiographic OA.
. GaitSmart might serve as additional non-invasive and easily applicable parameter to assess OA.
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Conventional radiography, despite its limitations, is the
gold standard imaging technique to assess progression
of tissue damage in OA. It enables detection of OA-
associated bony features but lacks the ability to directly
detect changes in other articular tissues (e.g. synovial
tissue, meniscus and cartilage) [1]. Besides, clinical
signs and symptoms of OA might be present even
2–3 years before radiographic changes appear on con-
ventional images [2]. Magnetic resonance imaging (MRI)
techniques do have the ability to visualize pathologies
that are not detectable on radiographs. However, the
high costs make it less suitable for standard use in clin-
ical practice [1]. OA patients learn to avoid pain, but this
avoidance leads to functional limitations and may
change movement patterns. Structural changes may
lead to functional limitations with a corresponding
change in gait. Questionnaires assessing pain and func-
tional limitations have the drawback of reflecting the
subjective opinion of a patient rather than an objective
measurement of the functional severity of OA. As such,
there is still an unmet need for non- or minimal invasive
techniques that add to the evaluation of OA.
Gait analysis might be such an additional measure-
ment. Significant correlations were found between gait
and the Western Ontario and McMaster Universities
Osteoarthritis Index (WOMAC) [3] and the Short Form
(36) health survey (SF-36) [4] subscales in patients fulfill-
ing the American College of Rheumatology (ACR) clinical
criteria for knee OA [5], radiographically confirmed
according to Kellgren and Lawrence (KL) [6, 7].
A commonly used gait parameter from tests per-
formed in an optical gait lab, the peak knee adduction
moment (KAM), was found to have a negative correl-
ation with cartilage thickness in OA knees, defined by
KL grade 2 [8]. KAM is increased in patients with
OA, compared with controls, and this increase is
higher for patients with severe OA than for patients
with mild OA [9, 10]. General gait parameters also dif-
fered between patients with knee OA and matched
(for sex, age, height and weight) control subjects,
walking at a similar speed. Knee flexion at heel strike
(beginning of stance phase) was less in OA patients
compared with controls [10]. Disadvantages of the op-
tical gait lab are the time and costs required to com-
plete one analysis.
The GaitSmartTM hardware solution is a user-friendly
and objective method to assess gait. It takes about
10–15 min and can be carried out virtually anywhere.
Knee flexion range of motion (ROM) in stance and swing
phase, measured using an earlier version of the
GaitSmart system than used in this study, is significantly
lower in OA patients, fulfilling the ACR clinical criteria for
OA, compared with healthy volunteers. A cut-off value
of 13.6 of knee ROM in stance phase could discrimin-
ate between knee OA patients and healthy controls with
a specificity of 0.952 and sensitivity of 0.783. Knee
ROM in swing phase was less discriminative [11].
As such, gait analysis, as an additional measurement,
may improve the assessment of presence and severity
of OA, in addition to standard outcome measures based
on radiographic measurements and patient reported
outcome measures (PROMs). The objectives of this
study are (i) to assess underlying domains measured by
GaitSmart parameters and whether these are additional
to established OA markers including PROMs and radio-
graphic parameters, (ii) to evaluate if gait analysis using
GaitSmart is related to the presence of radiographic
knee OA (ROA), and (iii) to evaluate if gait analysis using
the GaitSmart system is related to the severity of
ROA, on top of demographics and PROMs. If GaitSmart
provides a potential useful additional measurement to
assess OA, we hypothesize that GaitSmart parameters
measure domains different from PROMS and radio-
graphic outcomes, and that these GaitSmart domains
add to the relationship of demographics and PROMS
with the presence and severity of ROA.
Methods
Participants
Two hundred and ninety-seven people with knee OA
were included in the Applied Public-Private Research
enabling OsteoArthritis Clinical Headway (APPROACH)
study from January 2018 until April 2019 [age 66.5 (7.1)
years, female 230 (77%), BMI 28.1 (5.3) kg/m2] [12].
APPROACH is an exploratory, European, five-centre,
2-year prospective follow-up cohort study. It obtains ex-
tensive clinical, imaging, biomechanical and biochemical
parameters of participants recruited using machine
learning models based on retrospective and, to a limited
extent, prospectively collected patient data, to display a
high likelihood of radiographic joint space width loss
and/or knee pain over the 2-year course of the study.
For each participant the index knee was selected based
on ACR clinical criteria for knee OA, using history and
physical examination. If both knees fulfilled these crite-
ria, the index knee was the most painful knee according
to the participant. If both knees were equally painful, the
right knee was chosen. A radiograph of the index knee
was taken afterwards. Hence, the index knee was not
necessarily the knee with the highest KL grade, since
KL grade was determined after selecting an index knee
and index knees can have KL grade 0 or 1.
The study is being conducted in compliance with the
protocol Good Clinical Practice (GCP), the Declaration
of Helsinki, and the applicable ethical and legal regula-
tory requirements (for all countries involved), and is reg-
istered under ClinicalTrials.gov no.: NCT03883568. All
participants have received oral and written information
and provided written informed consent. The present
analysis focused on the baseline data.
GaitSmart measurement
The GaitSmart system uses six inertial measurement units
(IMU) to evaluate gait mechanics. These IMUs comprise
three tri-axial accelerometers and three tri-axial
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gyroscopes, making it possible to measure movements in
the sagittal and frontal plane [13]. After synchronizing the
IMUs using Poseidon software (Dynamic Metrics Limited,
Codicote, UK) they were attached to the body. Two IMUs
were placed on the pelvis, under the iliac crest, following
the alignment of the pelvis. Then two other IMUs were
placed on the widest part of the thighs, aligned in a
straight vertical line. The last two IMUs were placed on the
calves, on the belly of the gastrocnemius muscles [11, 13]
(see Supplementary Fig. S1, available at Rheumatology on-
line). Subsequently, participants were asked to stand still
for 5 s to calibrate the IMUs. The participants were then
asked to walk 15–20 m at their own self-selected speed
and return. After performing the test, the IMUs were
removed and attached to the laptop for analysis. The IMUs
are accurate to 0.11, although the measurement error
depends on positioning on the body. A previous study
showed a reproducibility of 62.8 and 63.4 for knee
ROM in swing and stance phase, respectively [11, 14].
Poseidon software was used to extract and analyse
data from the IMU sensors. The result is a report con-
taining ROM of pelvis, hips, thighs, knees in swing and
stance phase, and calves in the sagittal plane, stride
duration, medial–lateral movement of thighs and calves,
and symmetry scores between left and right. All param-
eters are presented in graphs and tables.
Fifteen GaitSmart parameters were selected for statistical
analysis based on previous research [11, 14] and clinical
expertise; ROM for both knees in swing and stance, both
hips and both calves were determined. Gait is considered
as a measurement at patient level as opposed to a meas-
urement at joint level. Therefore, the differences between
both legs were also determined and included in the analysis
as separate parameters. In addition, average stride dur-
ation, calculated speed and stride length were used.
Radiographic assessments
Standardized semi-flexed posterior–anterior weight bear-
ing knee radiographs of both knees were taken according
to Buckland-Wright et al. [15]. KL grading was performed
by one blinded observer. The intra- and interobserver cor-
relation were both previously found to be good (>0.83)
[6], and in the current study an intraclass correlation coef-
ficient (ICC) of 0.88 was found (using 10% of the radio-
graphs). Additionally, knee images digital analysis (KIDA)
[16] was performed by one single experienced observer.
Minimum joint space width of the tibiofemoral joint
(minJSW in mm), osteophyte area (mm2) and subchondral
bone density (mm aluminium equivalent) were used as
radiographic parameters. Previous studies demonstrated
an ICC of 0.73–0.99 for the different features [17].
Assessment of pain and function
Pain and function were evaluated at patient level
using the corresponding subscales of the Knee injury
and Osteoarthritis Outcome Score (KOOS) question-
naire [18], assessing pain in the most affected knee
(MAK), the Numeric Rating Scale (NRS) pain for both
knees and the Intermittent and Constant OsteoArthritis
Pain (ICOAP) questionnaire [19], again assessing pain in
the MAK. The KOOS questionnaire comprises nine items
for pain and 17 items for daily function, each question
scored on a 5-point scale. A normalized score is calcu-
lated where 0 means maximal limitations and 100 means
no limitations. The NRS pain consists of an 11-point
scale on which participants score pain from 0 (no pain)
to 10 (worst imaginable pain). The ICOAP questionnaire
contains 11 questions, five for constant pain and six for
intermittent pain, each question scored on a 5-point
scale. A higher total score reflects more pain.
Statistical analysis
Statistical analysis was performed using SPSS Statistics
version 25.0.0.2 (IBM Corp., Armonk, NY, USA). P-val-
ues <0.05 were considered statistically significant.
Relationship between individual GaitSmart
parameters and conventional parameters
A principal component analysis (PCA) was performed to
explore structure in relationships between individual
GaitSmart parameters and to reduce the total set of
parameters to a limited set of underlying domains. This
analysis was performed with GaitSmart parameters alone
as well as with radiographic parameters or PROMs as add-
itional parameters to see how or if these parameters would
underlie the same domains or measure something different.
PCA was also performed in different severity sub-
groups to investigate the stability of the identified under-
lying domains as associations in different OA severity
subgroups could differ. Subgroups were based on
radiographic parameters (KL grade and minJSW) and
PROMs (KOOS pain and daily function) using mean val-
ues as cut-offs to dichotomize.
Relationship with presence of radiographic knee OA
Logistic regression was used to evaluate the relationship
of identified GaitSmart domains with the presence of
ROA in a patient, defined as KL2 in at least one knee,
in addition to currently used parameters. Independent
variables were entered stepwise starting with demo-
graphic variables (age, sex and BMI), then KOOS pain
and KOOS daily function, and finally the GaitSmart
domains.
It was also evaluated whether the association of
the relevant GaitSmart domains with the presence of
ROA depended on pain severity, by testing inter-
action terms in the model. Statistically significant
interactions were retained in the model. The area
under the receiver operating characteristics curve
(AUC-ROC) was calculated for all models as a meas-
ure of (increase in) model fit.
Relation with severity of radiographic knee OA
To explore the relationship between identified GaitSmart
domains and the severity of ROA, in addition to currently
used parameters, linear regression was performed. The
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value of the MAK regarding minJSW (mm), osteophyte
area (mm2) and mean subchondral bone density (mm alu-
minium equivalent) was used as outcome within these
analyses. The independent variables were again entered
stepwise in the same blocks as in the analysis used for
the presence of ROA and interactions between KOOS
pain and relevant GaitSmart domains were tested, and, if
statistically significant, retained in the model.
Results
Participant characteristics
A successful GaitSmart analysis was performed for 284
participants. The 13 missing analyses were due to user
errors (n¼9) or technical issues (n¼ 4). Patient charac-
teristics of the total population and separately for those
with/without ROA are described in Table 1. The 13
excluded patients did not (statistically) significantly differ
from the patients included in the study (data not shown).
Principal component analysis
The PCA of GaitSmart parameters (GS) identified five
underlying domains (Supplementary Table S1, available
at Rheumatology online): one mainly related to ROM in
hips (GS Hip, component no. 1), one mainly related to
ROM of knees and calves (GS Knee, component no. 2),
and three mainly related to differences in either ROM of
knees and calves in swing phase (GS Difference Knee,
TABLE 1 Baseline characteristics of the included patients
Total ROA present ROA absent
(n 5 281a) (n 5 159) (n 5 122)
Demographics
Age, mean (S.D.), years 66.4 (7.0) 66.9 (7.2) 65.8 (6.9)
Female, n (%) 217 (77) 126 (79) 91 (74)
BMI, mean (S.D.), kg/m2 28.0 (5.4) 28.5 (5.3) 27.4 (5.4)
Patient reported outcome measurements
KOOS, mean (S.D.)
Pain 66.4 (18.8) 63.7 (17.8) 69.9 (19.4)
Daily function 69.3 (19.0) 67.4 (18.1) 71.6 (19.8)
Symptoms 69.7 (17.0) 66.5 (16.8) 73.7 (16.6)
Sports and recreational activities 43.0 (26.9) 36.6 (23.7) 51.0 (28.6)
Quality of life 53.4 (20.3) 49.5 (18.4) 58.5 (21.6)
NRS, mean (S.D.)
Index knee 4.5 (2.7) 4.7 (2.6) 4.3 (2.8)
Contralateral knee 2.9 (2.6) 3.0 (2.5) 2.9 (2.6)
Radiographic damage index kneeb
KL grade, n (%)
0 47 (17) 3 (2) 44 (36)
1 88 (31) 10 (6) 78 (64)
2 85 (30) 85 (54) —
3 51 (18) 51 (32) —
4 10 (4) 10 (6) —
KIDA
minJSW, mean (S.D.), mm 2.5 (1.2) 2.1 (1.4) 3.1 (0.8)
Osteophyte area, mean (S.D.), mm2 21.1 (19.8) 30.6 (21.5) 8.8 (5.5)
Subchondral bone density, mean (S.D.), mm Al eq 31.0 (5.1) 31.5 (5.1) 30.5 (5.0)
GaitSmart
Range of motion, mean (S.D.), 
Index knee in stance phase 15.8 (4.9) 15.0 (5.0) 17.0 (4.5)
Index knee in swing phase 58.0 (7.3) 56.4 (6.7) 60.0 (7.5)
Contralateral knee in stance phase 16.8 (5.1) 16.5 (5.0) 17.1 (5.3)
Contralateral knee in swing phase 59.0 (7.1) 58.0 (7.1) 60.3 (6.9)
Index calf 71.9 (6.6) 70.6 (6.9) 73.6 (5.9)
Contralateral calf 72.3 (6.3) 71.7 (6.6) 73.1 (5.9)
Index hip 33.4 (7.5) 33.1 (7.6) 33.7 (7.3)
Contralateral hip 34.0 (7.1) 34.1 (6.9) 33.9 (7.4)
Stride length, mean (S.D.), m 1.1 (0.2) 1.0 (0.2) 1.1 (0.2)
Duration per stride, mean (S.D.), s 1.1 (0.1) 1.1 (0.1) 1.1 (0.1)
Speed, mean (S.D.), m/s 1.0 (0.2) 1.0 (0.2) 1.0 (0.2)
aIn three participants the radiograph of the index knee was made incorrectly. bThe index knee in the APPROACH cohort
was not by definition the most radiographically damaged knee. Al eq: aluminium equivalent; BMI: body mass index,
KOOS: Knee injury and Osteoarthritis Outcome Score, NRS: Numeric Rating Scale, KL: Kellgren and Lawrence, KIDA:
knee image digital analysis, minJSW: minimum joint space width, ROA: radiographic osteoarthritis.
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component no. 3), ROM in hips (GS Difference Hip,
component no. 4) and ROM in knees during stance
phase (GS Difference Stance, component no. 5).
PROMs and radiographic parameters each formed an
additional component when added to the PCA, suggest-
ing that the parameters measure different domains of a
patient’s disease status (see Supplementary Table S1,
available at Rheumatology online). The PCA in different
subgroups showed that the domains identified were
relatively stable (data not shown). Therefore the
GaitSmart domains were used in further analyses.
Relation with the presence of radiographic knee OA
One hundred and fifty-nine participants (56%) had ROA
in at least one knee (KL grade 2). Logistic regression
showed that addition of GaitSmart data to the model
with demographics and PROMs improved the associ-
ation with the presence of ROA (Table 2 and Fig. 1);
Nagelkerke’s R2 increased from 0.075 to 0.150 when
adding GaitSmart parameters after demographics and
PROMs, but the discriminatory value of this model was
still only moderate (AUC¼ 0.698, 95% CI: 0.637, 0.760).
Sensitivity and specificity were 71.0% and 52.0%, re-
spectively, using a probability of 0.50 as cut-off. KOOS
pain [odds ratio (OR)¼ 0.964, 95% CI: 0.935, 0.994], GS
Knee (OR¼0.624, 95% CI: 0.457, 0.850), and GS
Difference Knee (OR¼ 1.319, 95% CI: 1.004, 1.733)
were statistically significant contributing factors.
The association of GS Knee and GS Difference Knee
with ROA statistically significantly depended on the level
of pain. With less pain the effect of GaitSmart domains
on the likeliness of having ROA decreased. Including
both interaction terms, the models’ Nagelkerke R2
increased to 0.212 (Table 2). The AUC-ROC increased
to 0.724 (95% CI: 0.665, 0.783; Table 2 and Fig. 1).
Relation with severity of radiographic knee OA:
minimum JSW
In the model with minJSW as outcome parameter age (B
(beta) ¼0.024, 95% CI: 0.043, 0.005), GS Hip
(B¼0.647, 95% CI: 1.148, 0.146), GS Knee
(B¼0.696, 95% CI: 1.174, 0.218), GS Difference Knee
(B¼0.153, 95% CI: 0.281, 0.025), and GS Difference
Stance (B¼0.134, 95% CI:0.262,0.005) were statistic-
ally significant contributing factors (Table 3). In this model
statistically significant interactions between KOOS pain and
GS Hip (B¼0.009, 95% CI: 0.002, 0.017) and between
KOOS pain and GS Knee (B¼ 0.012, 95% CI: 0.005, 0.019)
were found. The adjusted R2 of the final model, including
both statistically significant interaction terms, was 0.107.
Relation with severity of radiographic knee OA:
osteophyte area
In the model for osteophyte area sex (B¼10.117, 95%
CI: 16.409, 3.825) and GS Difference Knee
(B¼ 2.568, 95% CI: 0.120, 5.017) were statistically sig-
nificant contributors. Only one statistically significant
interaction term was found, between KOOS pain and
GS Knee (B¼0.228, 95% CI: 0.361, 0.095). The
final adjusted R2 was 0.132 (Table 4).
TABLE 2 Results of logistic regression analysis on presence of radiographic osteoarthritis
OR (95% CI)
Independent variable Model 1 Model 2 Model 3 Model 4
Constant 0.058 0.068 0.104 0.069
Age 1.025 (0.990, 1.061) 1.037 (1.000, 1.075) 1.032 (0.993, 1.073) 1.035 (0.994, 1.077)
Sex 1.418 (0.802, 2.509) 1.165 (0.643, 2.112) 0.923 (0.480, 1.773) 0.959 (0.486, 1.894)
BMI 1.043 (0.996, 1.092) 1.045 (0.994, 1.099) 1.034 (0.978, 1.093) 1.048 (0.989; 1.109)
KOOS pain 0.959 (0.931, 0.988) 0.964 (0.935, 0.994) 0.960 (0.930, 0.991)
KOOS daily function 1.029 (0.999, 1.059) 1.029 (0.998, 1.062) 1.032 (0.999, 1.066)
GS Hip 1.079 (0.819, 1.421) 1.071 (0.808, 1.421)
GS Knee 0.624 (0.457, 0.850) 2.794 (0.976, 8.000)
GS Difference Knee 1.319 (1.004, 1.733) 4.548 (1.453, 14.230)
GS Difference Hip 1.104 (0.848, 1.438) 1.162 (0.882, 1.531)
GS Difference Stance 1.202 (0.913, 1.582) 1.213 (0.916, 1.604)
KOOS pain  GS Knee 0.978 (0.962, 0.993)
KOOS pain  GS Difference Knee 0.981 (0.964, 0.998)
Nagelkerke R2 0.029 0.075 0.150 0.212
DR2 vs previous model 0.46 0.075 0.062
AUC (95% CI) 0.578 (0.510, 0.645) 0.641 (0.576, 0.706) 0.698 (0.637, 0.760) 0.724 (0.665, 0.783)
Sensitivity, % 81.9 74.8 71.0 74.2
Specificity, % 25.2 43.9 52.0 51.2
P-values <0.05 are indicated in bold. AUC: area under the curve; BMI: body mass index; GS: GaitSmartTM; KOOS: Knee
injury and Osteoarthritis Outcome Score; OR: odds ratio.
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FIG. 1 ROC curve
Diagonal segments are produced by ties. PROM: patient reported outcome measure; ROC: receiver operating
characteristic.
TABLE 3 Linear regression models for minJSW
Unstandardized B (95% CI)
Independent
variable
Model 1 Model 2 Model 3 Model 4
Constant 4.074 (2.555, 5.593)* 3.358 (1.671, 5.045)* 3.435 (1.717, 5.5153)* 3.398 (1.727, 5.069)*
Age 20.021 (20.040, 20.002) 20.24 (20.043, 20.005) 20.024 (20.044, 20.005) 20.024 (20.043, 20.005)
Sex 0.021 (0.296, 0.338) 0.094 (0.227, 0.416) 0.108 (0.230, 0.446) 0.072 (0.257, 0.401)
BMI 0.018 (0.043, 0.007) 0.010 (0.037, 0.016) 0.007 (0.034, 0.021) 0.010 (0.037, 0.017)
KOOS pain 0.011 (0.004, 0.026) 0.007 (0.008, 0.023) 0.005 (0.010, 0.020)
KOOS daily
function
0.001 (0.016, 0.015) 0.000 (0.016, 0.016) 0.003 (0.013, 0.019)
GS Hip 0.006 (0.149, 0.136) 20.647 (21.148, 20.146)
GS Knee 0.105 (0.045, 0.254) 20.696 (21.174, 20.218)
GS Difference Knee 20.139 (20.270, 20.008) 20.153 (20.281, 20.025)
GS Difference Hip 0.049 (0.179, 0.081) 0.070 (0.197, 0.057)
GS Difference Stance 20.147 (20.279, 20.015) 20.134 (20.262, 20.005)
KOOS pain  GS Hip 0.009 (0.002, 0.017)
KOOS pain  GS Knee 0.012 (0.005, 0.019)




P-values <0.05 are indicated in bold; *P<0.0001. B: Beta (represents slope); BMI: body mass index; GS: GaitSmartTM;
KOOS: Knee injury and Osteoarthritis Outcome Score.
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Relation with severity of radiographic knee OA:
subchondral bone density
In the model for mean subchondral bone density age
(B¼0.094, 95% CI: 0.183, 0.004), sex (B¼2.007,
95% CI: 3.573, 0.442), BMI (B¼0.250, 95% CI: 0.122,
0.377) and GS Knee (B¼0.880, 95% CI: 1.573,
0.187) were statistically significant contributing factors
(Table 5). No statistically significant interaction terms were
found. The adjusted R2 of the final model was 0.147.
Discussion
This study showed that GaitSmart parameters as meas-
ured at baseline in the APPROACH cohort can be
grouped in five main underlying domains: one mainly
related to ROM in hips (GS Hip, component no. 1), one
mainly related to ROM of knees and calves (GS Knee,
component no. 2), and three mainly related to differen-
ces in either ROM of knees and calves in swing phase
(GS Difference Knee, component no. 3), ROM in hips
(GS Difference Hip, component no. 4) and ROM in
knees during stance phase (GS Difference Stance, com-
ponent no. 5). The GaitSmart analysis relates to the
whole individual, including (possible) OA in multiple
joints. To account for this, differences in gait parameters
(component 3–5, see above) are also used as input vari-
ables. These five domains contain additional information
above radiographic parameters and PROMs and appear
TABLE 4 Linear regression models for osteophyte area
Unstandardized B (95% CI)
Independent variable Model 1 Model 2 Model 3 Model 4
Constant 5.257 (224.271, 34.785) 10.876 (222.215, 43.968) 23.592 (29.017, 56.202) 22.932 (29.066, 54.930)
Age 0.174 (20.194, 0.542) 0.224 (20.150, 0.598) 0.085 (20.282, 0.451) 0.074 (20.285, 0.433)
Sex 25.262 (211.424, 0.900) 26.258 (212.563, 0.046) 210.401 (216.811, 23.991) 210.117 (216.409, 23.825)
BMI 0.385 (20.096, 0.865) 0.332 (20.188, 0.852) 20.012 (20.534, 0.509) 0.073 (20.442, 0.587)
KOOS pain 20.176 (20.478, 0.127) 20.130 (20.426, 0.166) 20.119 (20.410, 0.171)
KOOS daily function 0.072 (20.235, 0.378) 0.164 (20.142, 0.469) 0.153 (20.147, 0.453)
GS Hip 22.061 (24.762, 0.641) 22.060 (24.710, 0.591)
GS Knee 27.118 (29.956, 24.280)* 7.839 (21.305, 16.983)
GS Difference Knee 2.230 (20.257, 4.718) 2.568 (0.120, 5.017)
GS Difference Hip 1.014 (21.456, 3.484) 1.336 (21.095, 3.767)
GS Difference Stance 1.745 (20.760, 4.249) 1.620 (20.838, 4.079)
KOOS pain  GS Knee 20.228 (20.361, 20.095)
Adjusted R2 0.011 0.013 0.098 0.132
DR2 vs previous model 0.002 0.085 0.034
P-values <0.05 are indicated in bold; *P<0.0001. B: Beta (represents slope); BMI: body mass index; GS: GaitSmartTM;
KOOS: Knee injury and Osteoarthritis Outcome Score.
TABLE 5 Linear regression models for mean subchondral bone density
Unstandardized B (95% CI)
Independent variable Model 1 Model 2 Model 3
Constant 30.628 (23.665, 37.590)* 33.067 (25.260, 40.874)* 34.272 (26.309, 42.234)*
Age 20.083 (20.170, 0.004) 20.078 (20.166, 0.010) 20.094 (20.183, 20.004)
Sex 21.507 (22.960, 20.054) 21.618 (23.106, 20.131) 22.007 (23.573, 20.442)
BMI 0.323 (0.210, 0.436)* 0.293 (0.171, 0.416)* 0.250 (0.122, 0.377)*
KOOS pain 20.008 (20.080, 0.063) 0.002 (20.070, 0.074)
KOOS daily function 20.019 (20.091, 0.054) 20.009 (20.083, 0.066)
GS Hip 20.351 (21.011, 0.309)
GS Knee 20.880 (21.573, 20.187)
GS Difference Knee 0.223 (20.385, 0.830)
GS Difference Hip 0.094 (20.509, 0.697)
GS Difference Stance 0.569 (20.043, 1.180)
Adjusted R2 0.128 0.129 0.147
DR2 vs previous model 0.001 0.018
P-values <0.05 are indicated in bold; *P<0.0001. B: Beta (represents slope); BMI: body mass index; GS: GaitSmartTM;
KOOS: Knee injury and Osteoarthritis Outcome Score.
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stable in different subgroups. The adjusted R2 of the lin-
ear regression models shows moderate correlations with
the severity of ROA. However, the increase in adjusted
R2 compared with the models using only demographics
and PROMs is considerably.
Therefore, combining GaitSmart parameters in five
‘domains’ as proposed provides a concise set of rele-
vant parameters that may have value as additional out-
come measurements to assess OA and can be further
validated in future analyses.
The main limitation of this study is the translation to
the general OA population. APPROACH participants
were selected based on a high probability of structural
and/or pain progression. This may restrict the generaliz-
ability of the results. However, the domains identified
were stable over subgroups of severity, and selection
bias regarding the associations found, taking into ac-
count other demographic and PROM outcomes, is likely
limited. However, the specific size of the association
may be different in e.g. very early disease. Another limi-
tation is the lack of follow-up data. Any prognostic value
of the GaitSmart parameters or any time relationship
(e.g. does progression lead to a difference in GaitSmart
or the other way around?), which is highly relevant,
could not be evaluated. Furthermore, the development
of gait characteristics over time might be of additional
value above a single gait analysis.
The association of GaitSmart (specifically the GS
Difference Knee domain) additional to other parameters,
was highest for osteophyte area. One can imagine that
a certain relationship exists between the size of osteo-
phytes and limitation in knee movement. The concept of
mechanical hindering has also been linked to the pres-
ence of a relationship between osteophytes and synovial
inflammation [20, 21].
In this study, the severity of ROA was evaluated by
parameters related to cartilage (minJSW) and bone
(mean subchondral bone density). The fact that the as-
sociation is limited indicates that other joint structures
(e.g. ligaments and/or muscles) also play a substantial
role in someone’s gait. Although the exclusion criteria of
APPROACH rule out secondary osteoarthritis and gener-
alized pain syndromes, other comorbidities influencing
gait (e.g. neuromuscular disorders) might also be pre-
sent. Therefore, contribution of other joint structures
and/or comorbidities related to gait might have influ-
enced the relations found between gait and ROA. Some
people are also able to manage pain better when walk-
ing than others, and neuropathic OA pain might be
involved. These may influence the possibility of obtain-
ing strong relations, but given the finding that GaitSmart
measures another underlying domain of OA, these asso-
ciations probably should not be too strong.
The association with the presence of ROA (KL grade
2) was quite strong for GaitSmart. This is in line with
Naili et al. who found that peak KAM and a positive
KAM impulse were able to discriminate between mild
OA (KL grade 1–2) and severe OA (KL grade 3–4) [9].
Using the GaitSmart system has the benefit of assessing
the full motion of walking, in contrast to peak value
measurements, which only represent a single moment
during walking [22].
The gait analysis used by Naili et al. was conducted
at motion analysis laboratories. At present, 3D optical
gait analysis is considered to be the gold standard for
testing a person’s movement [23]. The strong advantage
of the GaitSmart system is the possibility of using it in a
natural environment, since no cameras and force plates
are required. Moreover, significantly less time is needed
to perform a GaitSmart measurement, 15 min, where
measurements in gait laboratories require up to half a
day [23]. When comparing the use of IMUs to 3D ana-
lysis using an optical tracking system, no differences
were found in determining pelvic tilt and knee ROM. The
intraclass correlation coefficients were 0.83 (0.72–0.90)
for right knee ROM, 0.86 (0.77–0.92) for left knee ROM,
0.75 (0.34–0.89) for right hip ROM and 0.73 (0.22–0.89)
for left hip ROM [13]. This indicates that GaitSmart pro-
duces valid data for pelvic tilt and, more importantly in
our case, knee ROM.
Factors that alter proper joint biomechanics trigger the
onset or acceleration of the degenerative process of OA,
facilitating the beginning of structural changes and clinical
symptoms [24]. The reverse sequence of events will likely
occur as well: degenerative and inflammatory changes in
the joint will alter biomechanics. Gait characteristics
related to medial compartment knee OA depend on the
OA severity [10]. Patients with less severe knee OA may
adopt a strategy of gait compensation, lowering the load
at the medial compartment, reducing their progression
risk, whereas patients with more severe knee OA are un-
able to lower the load on the medial compartment,
increasing the risk for disease progression [10]. By adapt-
ing the gait pattern in an early OA stage, assisting the nat-
ural compensation strategy, it might be possible to slow
down disease progression and postpone surgery.
Therefore, first a prognostic value of GaitSmart parameters
for disease progression should be established. These data
become available within the APPROACH project when
follow-up data are collected. When gait characteristics
prove to be possibly modifiable prognostic factors, early
detection of an unfavourable gait in combination with ad-
equate adaptation strategies to this might become a feas-
ible preventive strategy.
Patients scheduled for total knee arthroplasty had a typ-
ical OA gait pattern (reduced knee ROM in stance and
swing phase) before surgery. Fifty-two weeks post-oper-
ation, two-thirds of the patients still had OA gait character-
istics, even though pain was reduced [25]. This study also
suggested a potential value of gait analysis, in this case in
the rehabilitation after joint replacement. GaitSmart could
monitor ROM progression of patients after total knee
arthroplasty and identify patients that do not improve and
might benefit from additional rehabilitation.
In conclusion, our study shows that GaitSmart pro-
vides additional information above parameters currently
used to asses OA, and is associated with the presence
of ROA and, to a limited extent, the severity of OA
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above demographics and PROMs. This may indicate
that GaitSmart could be an additional parameter to
asses OA, but longitudinal studies are required to evalu-
ate how GaitSmart could optimally serve as an addition-
al non-invasive and easily applicable parameter to
assess knee OA.
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